pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,098 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology574Rare Disease284Immunology229Cardiology193Hematology159Pulmonology131Vaccines99Psychiatry & CNS
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 2mo ago↗ source
  • Cytospire hauls in $83M for a new type of T cell engager
    The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
    A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
    STAT · 2mo ago↗ source
← prev
page 39 of 44
next →
22
fda press21
fda medwatch17
87
Ophthalmology86
Pain75
Endocrinology & Metabolism52
Dermatology51
  • STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
    France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
    STAT · 2mo ago↗ source
  • Opinion: Mifepristone court ruling makes drug development riskier for everyone
    The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.
    STAT · 2mo ago↗ source
  • Celcuity strengthens case for ASCO-spotlighted breast cancer drug
    The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
    BioPharma Dive · 2mo ago↗ source
  • Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
    The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
    STAT · 2mo ago↗ source
  • Researchers urge study of paternal deaths, though a new paper finds fatherhood is protective
    A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention
    STAT · 2mo ago↗ source
  • STAT+: Pump the brakes on AI, buddy; and deposition deadlock
    It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
    STAT · 2mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
    BioPharma Dive · 2mo ago↗ source
  • UCB to acquire maker of antibody treatments for autoimmune diseases
    A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
    STAT · 2mo ago↗ source
  • What to know about hantavirus, the illness suspected in a cruise ship outbreak
    A rodent-borne illness is suspected of causing an outbreak aboard a cruise ship that has killed three people and sickened others. Here's what to know about hantavirus.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
    Two drugmakers asked the U.S. Supreme Court to restore mail-order access to the abortion pill mifepristone, after an appeals court suspended deliveries
    STAT · 2mo ago↗ source
  • Federal court blocks mailing of mifepristone
    Longevity "blue zones," an update on uterine transplant science, and more Morning Rounds health news
    STAT · 2mo ago↗ source
  • STAT+: Biotech raises $42 million to run Huntington’s disease trial
    Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
    STAT · 2mo ago↗ source
  • UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
    The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
    BioPharma Dive · 2mo ago↗ source
  • What is your AI drug repurposing strategy missing?
    Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
    BioPharma Dive · 2mo ago↗ source
  • Immigration changes are driving foreign researchers to leave the U.S. — or not come to begin with
    Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.
    STAT · 2mo ago↗ source
  • Opinion: Are blue zones real? Answering that question is harder than ever
    "Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
    STAT · 2mo ago↗ source
  • Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies
    China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
    STAT · 2mo ago↗ source
  • Federal appeals court blocks mailing of abortion pill mifepristone
    Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.
    STAT · 2mo ago↗ source
  • Opinion: What do medical students think about their education?
    “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
    STAT · 2mo ago↗ source
  • Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school
    “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
    STAT · 2mo ago↗ source
  • Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
    Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
    STAT · 3mo ago↗ source